Ausgabe 1/2014
Inhalt (23 Artikel)
Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison
Paul Craddy, Hannah-Jayne Palin, K. Ian Johnson
The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review
Janet B. McGill
Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues
Sanjay Kalra
Carcinogenicity Risk Assessment Supports the Chronic Safety of Dapagliflozin, an Inhibitor of Sodium–Glucose Co-Transporter 2, in the Treatment of Type 2 Diabetes Mellitus
Timothy P. Reilly, Michael J. Graziano, Evan B. Janovitz, Thomas E. Dorr, Craig Fairchild, Francis Lee, Jian Chen, Tai Wong, Jean M. Whaley, Mark Tirmenstein
Long-term Effects of Mitiglinide in Japanese Diabetics Inadequately Controlled with DPP-4 Inhibitor or Biguanide Monotherapy
Kohei Kaku, Nobuya Inagaki, Naoki Kobayashi
Safety, Tolerability, and Efficacy of Insulin Aspart in People with Type 2 Diabetes, as Biphasic Insulin Aspart or with Basal Insulin: Findings from the Multinational, Non-Interventional A1chieve Study
Issam Hajjaji, Siddharth Shah, Yuxiu Li, Vinay Prusty, Youcef Benabbas, Philip D. Home
Type 2 Diabetes Mellitus Management and Body Mass Index: Experiences with Initiating Insulin Detemir in the A1chieve Study
Mohammed E. Khamseh, Vinay Prusty, Zafar Latif, Guillermo Gonzalez-Galvez, Guillermo Dieuzeide, Alexey Zilov
Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG Study
Borje Darpo, Meijian Zhou, Jessica Matthews, Hui Zhi, Malcolm A. Young, Caroline Perry, Rickey R. Reinhardt
Self-Reported Frequency and Impact of Hypoglycemic Events in Spain
Domingo Orozco-Beltrán, Pedro Mezquita-Raya, Antonio Ramírez de Arellano, Manuel Galán
Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus
Masato Odawara, Izumi Hamada, Manabu Suzuki
Real-Life Effectiveness and Tolerability of Vildagliptin and Other Oral Glucose-Lowering Therapies in Patients with Type 2 Diabetes in Germany
Rüdiger Göke, Giovanni Bader, Markus Dworak
Efficacy of Liraglutide in a Real-Life Cohort
Anthony Heymann, Yasmin Maor, Inbal Goldstein, Lora Todorova, Perlit Schertz-Sternberg, Avraham Karasik
Use of Vildagliptin in Management of Type 2 Diabetes: Effectiveness, Treatment Persistence and Safety from the 2-Year Real-Life VILDA Study
Dominique Simon, Bruno Detournay, Evelyne Eschwege, Stephane Bouée, Jacques Bringer, Claude Attali, Sylvie Dejager
Early Discontinuation and Restart of Insulin in the Treatment of Type 2 Diabetes Mellitus
Haya Ascher-Svanum, Maureen J. Lage, Magaly Perez-Nieves, Matthew D. Reaney, Joanne Lorraine, Angel Rodriguez, Michael Treglia
Metabolic Effects of Basal or Premixed Insulin Treatment in 5077 Insulin-Naïve Type 2 Diabetes Patients: Registry-Based Observational Study in Clinical Practice
Björn Eliasson, Nils Ekström, Sara Bruce Wirta, Anders Odén, MirNabi Pirouzi Fard, Ann-Marie Svensson
Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus
Tim Heise, Leszek Nosek, Carsten Roepstorff, Suresh Chenji, Oliver Klein, Hanne Haahr
Dapagliflozin Added to Glimepiride in Patients with Type 2 Diabetes Mellitus Sustains Glycemic Control and Weight Loss Over 48 Weeks: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial
Krzysztof Strojek, Kun-Ho Yoon, Veronika Hruba, Jennifer Sugg, Anna Maria Langkilde, Shamik Parikh
Sitagliptin Improves the Impaired Acute Insulin Response during a Meal Tolerance Test in Japanese Patients with Type 2 Diabetes Mellitus: A Small-Scale Real-World Study
Tsuyoshi Ohkura, Youhei Fujioka, Keisuke Sumi, Risa Nakanishi, Hideki Shiochi, Naoya Yamamoto, Kazuhiko Matsuzawa, Shoichiro Izawa, Hiroko Ohkura, Masahiko Kato, Shin-ichi Taniguchi, Kazuhiro Yamamoto
Diabetes Education: the Experiences of Young Adults with Type 1 Diabetes
Janice Wiley, Mary Westbrook, Janet Long, Jerry R. Greenfield, Richard O. Day, Jeffrey Braithwaite
Effects of Exenatide in a Morbidly Obese Patient with Type 2 Diabetes
Miyako Kishimoto, Mitsuhiko Noda
Choosing Appropriate Glucagon-like Peptide 1 Receptor Agonists: A Patient-Centered Approach
Sanjay Kalra
Testing the Therapeutic Equivalence of Alogliptin, Linagliptin, Saxagliptin, Sitagliptin or Vildagliptin as Monotherapy or in Combination with Metformin in Patients with Type 2 Diabetes
Andrea Messori, Valeria Fadda, Dario Maratea, Sabrina Trippoli, Claudio Marinai
Erratum to: Efficacy of Liraglutide in a Real-Life Cohort
Anthony Heymann, Yasmin Maor, Inbal Goldshtein, Lora Todorova, Perlit Schertz-Sternberg, Avraham Karasik